Breakthrough E-selectin inhibitor therapy for elderly AML
Description: E-selectin is involved in the progression of acute myeloid leukemia (AML), playing a key role in angiogenesis, thus making it a therapeutic target. In this interview, Marina Konopleva, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the clinical trial of the E-selectin inhibitor GMI-1271 in combination with high-dose cytarabine for relapsed/refractory and newly diagnosed elderly AML (NCT02306291). Excitingly, this drug has now been granted FDA breakthrough therapy designation. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Shared By : VJHemOnc
Posted on : 01/09/18
Added : 9 months ago